95651-20-0Relevant articles and documents
Novel orally active NPY Y5 receptor antagonists: Synthesis and structure-activity relationship of spiroindoline class compounds
Sakamoto, Toshihiro,Moriya, Minoru,Tsuge, Hiroyasu,Takahashi, Toshiyuki,Haga, Yuji,Nonoshita, Katsumasa,Okamoto, Osamu,Takahashi, Hirobumi,Sakuraba, Aya,Hirohashi, Tomoko,Shibata, Takunobu,Kanno, Tetsuya,Ito, Junko,Iwaasa, Hisashi,Gomori, Akira,Ishihara, Akane,Fukuroda, Takahiro,Kanatani, Akio,Fukami, Takehiro
, p. 5015 - 5026 (2009)
Spiroindoline urea derivatives, designed to act as NPY Y5 receptor antagonists, were synthesized and their structure-activity relationships were investigated. Of these derivatives, compound 3a showed good Y5 binding affinity with favorable pharmacokinetic
HUMAN PLASMA KALLIKREIN INHIBITORS
-
Page/Page column 74-75, (2017/05/10)
Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.